Allstate
ALL
$231.55
+4.04%
The Allstate Corporation is a leading US property and casualty insurer, with its core business focused on personal auto insurance, complemented by homeowners insurance and other protection products. As one of the largest players in its industry, Allstate operates a distinct distribution model primarily through a network of approximately 6,000 exclusive agents, positioning it as a traditional, agent-centric insurer in a competitive landscape. The current investor narrative is dominated by the company's ongoing recovery from prior underwriting challenges, with recent financial results showing a significant rebound in profitability, driving debate around the sustainability of this margin expansion and the company's ability to navigate inflationary pressures in claims costs.…
ALL
Allstate
$231.55
Related headlines
Investment Opinion: Should I buy ALL Today?
Rating: Hold. The core thesis is that Allstate presents a compelling but fully priced value story, where the dramatic earnings recovery is already reflected in the stock's run to near 52-week highs, leaving limited near-term upside without evidence of sustainable margin expansion.
Supporting evidence includes the deeply discounted trailing P/E of 5.38x and Price-to-Sales of 0.82x versus sector peers, the robust balance sheet (Debt/Equity of 0.24), and massive TTM free cash flow of $9.88B. However, the forward P/E of 8.42x indicates expected earnings moderation, and the stock's 13.0% 1-year gain has largely captured the initial re-rating. The stock's defensive beta of 0.19 and 2.1% dividend yield offer some downside protection but limit explosive growth potential.
The thesis would upgrade to a Buy if the company demonstrates sustainability of Q4-level margins (gross margin >50%) into the next two quarters, confirming a structural improvement. It would downgrade to a Sell if quarterly net income falls below $2.5B or if revenue growth turns negative, signaling the recovery has stalled. Relative to its own history and the sector, the stock is fairly valued—the market is not paying a premium for peak earnings it doubts will last, nor a deep discount for a broken business.
Sign up to view all
ALL 12-Month Price Forecast
The outlook is balanced with a skew towards the base case. The stock's fate hinges entirely on the trajectory of underwriting margins. The bull case is plausible but requires proof of sustainability that the market currently doubts, as reflected in the low P/E. The bear case, while lower probability, carries significant downside to the 52-week low. The stance would upgrade to bullish on consecutive quarters of margin stability above 20% and downgrade to bearish on a quarterly net income miss below $2.0B. For now, the risk/reward appears balanced, favoring a patient, watchful approach.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Allstate's 12-month outlook, with a consensus price target around $301.02 and implied upside of +30.0% versus the current price.
Average Target
$301.02
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$185 - $301
Analyst target range
Analyst coverage for Allstate is limited, with only 5 analysts providing estimates, indicating this large-cap stock may have subdued institutional research interest relative to its size. The consensus leans neutral to cautiously optimistic, with recent institutional ratings including 'Outperform' from Mizuho and Keefe Bruyette & Woods, 'Equal Weight' from Wells Fargo, and a notable downgrade from TD Cowen to 'Hold' from 'Buy' in January 2026. The wide range in EPS estimates, from a low of $23.68 to a high of $26.59, signals meaningful uncertainty among analysts regarding the company's future earnings power, which can contribute to stock price volatility and less efficient price discovery in the absence of broader coverage.
Bulls vs Bears: ALL Investment Factors
The bull case, supported by a dramatic profitability recovery and a deeply discounted valuation, currently holds stronger evidence. The bear case rightly questions the sustainability of peak margins amid modest revenue growth. The single most important tension in the investment debate is whether the Q4 2025 margin expansion (gross margin to 53.0%, net margin to 23.1%) represents a new, sustainable underwriting paradigm or a cyclical peak that will mean-revert. The resolution of this tension, as seen in upcoming quarterly margins, will dictate whether the stock re-rates higher from its low P/E or faces multiple compression as earnings normalize.
Bullish
- Exceptional Profitability Rebound: Q4 2025 net income surged to $3.83B, yielding a net margin of 23.1%, up from 11.8% in the year-ago quarter. Gross margin expanded dramatically to 53.0% from 30.1%, demonstrating successful pricing and underwriting discipline that has restored core earnings power.
- Deeply Discounted Valuation: The stock trades at a trailing P/E of 5.38x and a forward P/E of 8.42x, both significantly below typical Property & Casualty industry averages. This valuation is also far below its own 5-year historical range, which has seen P/E multiples above 30x, presenting a potential value opportunity if earnings stabilize.
- Robust Balance Sheet & Cash Flow: Allstate boasts a strong financial position with a low debt-to-equity ratio of 0.24 and trailing twelve-month free cash flow of $9.88B. This provides ample internal capital to fund operations, shareholder returns, and strategic initiatives without financial strain.
- Strong Technical Momentum: The stock is up 13.0% over the past year and is trading near its 52-week high of $227.62, indicating sustained positive momentum. Its low beta of 0.19 suggests it has been a stable, defensive performer relative to the volatile broader market.
Bearish
- Unsustainable Peak Margins: The Q4 2025 gross margin of 53.0% and net margin of 23.1% are exceptionally high for the insurance industry and likely cyclical. The forward P/E of 8.42x being higher than the trailing P/E of 5.38x indicates the market expects earnings to moderate from these peak levels.
- Limited Revenue Growth: Q4 2025 revenue grew only 1.5% year-over-year to $16.59B, following a pattern of modest and volatile quarterly results. This tepid top-line growth challenges the narrative of a durable recovery and limits multiple expansion potential.
- Elevated Analyst Uncertainty: Only 5 analysts cover this large-cap stock, and their EPS estimates range widely from $23.68 to $26.59, signaling significant disagreement on future earnings. This limited coverage and high dispersion can lead to inefficient price discovery and increased volatility.
- Recent Relative Underperformance: The stock has underperformed the S&P 500 (SPY) by 12.0 percentage points over the past year (ALL +13.0% vs. SPY +25.0%). This 1-month decline of -1.5% against a strong 3-month gain suggests the recent rally may be losing steam, prompting profit-taking.
ALL Technical Analysis
The stock is in a sustained uptrend, evidenced by a 13.03% gain over the past year, and is currently trading near the upper end of its 52-week range, approximately 2.4% below its 52-week high of $227.62. This positioning near highs suggests strong momentum but also raises questions about potential overextension, especially given the recent pullback from the peak. Recent momentum shows a divergence, with the stock down 1.52% over the past month, contrasting with the positive 7.56% gain over the last three months; this 1-month decline against a strong 1-year trend signals a potential consolidation or profit-taking phase following the earlier advance. Key technical levels are clearly defined by the 52-week high of $227.62 as immediate resistance and the 52-week low of $188.08 as major support; a decisive breakout above resistance would confirm the bullish trend's resumption, while a breakdown below support could indicate a deeper correction. The stock's beta of 0.19 indicates it is significantly less volatile than the broader market (SPY), which has implications for risk-adjusted returns and suggests the stock may be viewed as a defensive holding within the financial sector.
Beta
0.19
0.19x market volatility
Max Drawdown
-11.5%
Largest decline past year
52-Week Range
$188-$232
Price range past year
Annual Return
+16.7%
Cumulative gain past year
| Period | ALL Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | -1.6% |
| 3m | +13.1% | +11.7% |
| 6m | +10.8% | +6.3% |
| 1y | +16.7% | +22.2% |
| ytd | +13.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALL Fundamental Analysis
Allstate's revenue trajectory shows modest growth with stabilization, as Q4 2025 revenue reached $16.59 billion, representing a 1.52% year-over-year increase, though this follows a more volatile pattern across recent quarters with Q3 2025 revenue at $17.06 billion and Q2 at $16.55 billion. The company's profitability has dramatically improved, with Q4 2025 net income surging to $3.83 billion, yielding a robust net margin of 23.1%, and gross margin expanding significantly to 52.96% from 30.1% in the year-ago quarter, indicating successful pricing actions and underwriting discipline. The balance sheet and cash flow position is strong, highlighted by a low debt-to-equity ratio of 0.24, a return on equity of 33.6%, and substantial trailing twelve-month free cash flow of $9.88 billion, which provides ample internal capital to fund operations, shareholder returns, and growth initiatives without reliance on excessive external financing.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.52%
Latest Quarter
Free Cash Flow
$9.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALL Overvalued?
Given Allstate's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 5.38x and a forward PE of 8.42x; the higher forward multiple suggests the market anticipates some moderation from the exceptionally high profitability seen in the most recent quarter. Compared to sector averages, Allstate's valuation appears discounted; its trailing PE of 5.38x and Price-to-Sales (PS) ratio of 0.82x are typically below those of the broader Property & Casualty insurance industry, suggesting the market may be pricing in cyclical risks or underestimating the durability of the recent earnings recovery. Historically, the current trailing PE of 5.38x sits well below its own 5-year range, which has seen periods above 30x during profitability troughs; this low historical positioning could indicate a value opportunity if the company sustains its current level of earnings, though it also reflects the market's memory of past volatility.
PE
5.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1458x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
4.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the potential mean reversion of currently exceptional profitability. The Q4 2025 net margin of 23.1% and gross margin of 53.0% are far above historical norms and likely incorporate favorable but transient claims trends. A reversion to the Q4 2024 net margin of 11.8% would cut earnings by nearly half, severely impacting the valuation support from the current P/E of 5.38x. Furthermore, revenue growth is anemic at 1.5% YoY, indicating the company's recovery is purely margin-driven and lacks a top-line catalyst, creating dependency on perfect underwriting execution.
Market & Competitive Risks include valuation compression if peak earnings prove unsustainable. The stock trades near its 52-week high, and its forward P/E of 8.42x, while low, already anticipates some earnings moderation. The stock's low beta of 0.19, while defensive, also suggests it may not participate fully in broad market rallies, as evidenced by its significant underperformance versus the SPY over the past year. Competitive and regulatory pressures in the core auto insurance market pose constant threats to pricing power and could trigger a new cycle of margin pressure.
Worst-Case Scenario involves a perfect storm of rising claims costs (due to inflation or catastrophic events), competitive pricing pressure, and a broader market downturn. This could trigger a rapid collapse in margins back to or below historical averages, leading to significant earnings misses and analyst downgrades. The realistic downside could see the stock retreat to its 52-week low of $188.08, representing a potential loss of approximately -15% from the current price of $221.17. A more severe bear case, incorporating multiple compression on lower earnings, could see losses approach -25% to -30%.
FAQ
The primary risk is margin compression: the Q4 2025 net margin of 23.1% is likely cyclical, and a reversion to historical levels would drastically cut earnings and compress the P/E multiple. Second is competitive risk in its core auto insurance market, which could pressure pricing. Third is macroeconomic risk, as inflation can drive up claims costs. Fourth is execution risk, given the company's reliance on its exclusive agent network in a digitally evolving industry. The severity is highest for the margin risk, as it directly underpins the current valuation support.
The 12-month forecast presents three scenarios. The base case (60% probability) sees the stock trading between $215 and $235, as earnings normalize modestly from peaks. The bull case (25% probability) targets $240-$260 if margins hold, driving a P/E re-rating. The bear case (15% probability) sees a drop to $188-$205 if margins collapse. The base case is most likely, anchored by the analyst average EPS estimate and the current forward P/E. The key assumption is that net income stabilizes around $2.5B-$3.0B per quarter, not the Q4 peak of $3.83B.
ALL appears fairly valued in context. Its trailing P/E of 5.38x and Price-to-Sales of 0.82x are deeply discounted compared to sector averages and its own history, suggesting undervaluation. However, the forward P/E of 8.42x is higher, indicating the market expects earnings to fall from recent peaks. This dichotomy means the stock is cheap on trailing earnings but fairly priced on anticipated future earnings. The valuation implies the market is paying a fair price for earnings it believes will normalize, not a premium for sustained hyper-profitability.
ALL is a good buy for a specific investor profile: value-oriented or defensive investors seeking a low-volatility holding with a margin-of-safety valuation. The trailing P/E of 5.38x offers significant downside protection if earnings merely stabilize, not grow. However, with the stock near its 52-week high and revenue growth minimal, near-term upside is likely capped without proof that recent peak margins are sustainable. It is a less compelling buy for growth investors. The decision hinges on one's belief in the durability of the Q4 2025 profitability rebound.
ALL is more suitable for a medium- to long-term investment horizon (2+ years). Its low beta of 0.19 and 2.1% dividend yield make it a poor candidate for short-term trading, as it typically exhibits lower volatility and slower price movements. A longer horizon allows time to assess whether the profitability recovery is structural and for the valuation discount to potentially close. The stock's character as a value/defensive play aligns with a patient, income-augmenting strategy rather than short-term speculation.